Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -383.03% is 27% above its 5-year average of -523.37%, around the middle of its 5-year range (-983.44%–-93.36%).
As of the fiscal period ended Tuesday, June 30, 2026. 27.26% above its 12-month average of -526.55%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -383.03%.
RETURN ON EQUITY (ROE)
-383.03%
RETURN ON EQUITY (ROE) AVG TTM
-526.55%
RETURN ON EQUITY (ROE) AVG 3Y
-590.83%
RETURN ON EQUITY (ROE) AVG 5Y
-523.37%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+27.26%
CURRENT VS 3Y AVG
+35.17%
CURRENT VS 5Y AVG
+26.81%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-811.76%
vs the sector median at left
Ernexa Therapeutics Inc.
Market Cap
$3.65M
Return on Equity (ROE)
-383.03%
TTM Avg
-526.55%
3Y Avg
-590.83%
5Y Avg
-523.37%
Market Cap
$3.65M
Return on Equity (ROE)
N/A
TTM Avg
5741.84%
3Y Avg
2797.55%
5Y Avg
1847.94%
Market Cap
$3.63M
Return on Equity (ROE)
-5.85%
TTM Avg
-5.85%
3Y Avg
-10.40%
5Y Avg
7.36%
Market Cap
$3.53M
Return on Equity (ROE)
-282.13%
TTM Avg
-313.25%
3Y Avg
-153.55%
5Y Avg
-153.55%
Market Cap
$3.50M
Return on Equity (ROE)
-89.85%
TTM Avg
30.83%
3Y Avg
-183.24%
5Y Avg
-146.59%
Market Cap
$3.49M
Return on Equity (ROE)
-40.20%
TTM Avg
193.27%
3Y Avg
-10433.46%
5Y Avg
-6975.64%
Market Cap
$3.90M
Return on Equity (ROE)
-310.33%
TTM Avg
-204.84%
3Y Avg
-115.20%
5Y Avg
-69.88%
Market Cap
$3.93M
Return on Equity (ROE)
-437.15%
TTM Avg
-328.44%
3Y Avg
-188.67%
5Y Avg
-533.64%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | $3.65M | -383.03% | -526.55% | -590.83% | -523.37% |
| Evogene Ltd. (EVGN)vs › | $3.65M | N/A | 5741.84% | 2797.55% | 1847.94% |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.63M | -5.85% | -5.85% | -10.40% | 7.36% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | -282.13% | -313.25% | -153.55% | -153.55% |
| Moolec Science S.A. (MLEC)vs › | $3.50M | -89.85% | 30.83% | -183.24% | -146.59% |
| Eocene Ltd. (EOCN)vs › | $3.50M | N/A | N/A | N/A | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | -40.20% | 193.27% | -10433.46% | -6975.64% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $3.90M | -310.33% | -204.84% | -115.20% | -69.88% |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.93M | -437.15% | -328.44% | -188.67% | -533.64% |
| Nexalin Technology, Inc. (NXL)vs › | $3.30M | -591.60% | -213.16% | -150.57% | -4.48% |
ROE
-383.0%
ROA
-194.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -383.03% |
| 2026-03-31 | -166.02% |
| 2025-12-31 | -586.55% |
| 2025-09-30 | -513.73% |
| 2025-06-30 | -983.44% |
| 2023-12-31 | -970.35% |
| 2023-09-30 | -561.54% |
| 2023-06-30 | -562.00% |
| 2023-03-31 | -279.36% |
| 2022-12-31 | -202.99% |
| 2022-09-30 | -318.18% |
| 2022-06-30 | -722.04% |
| 2022-03-31 | -655.06% |
| 2021-12-31 | -480.49% |
| 2021-09-30 | -895.77% |
| 2021-06-30 | -93.36% |
| 2020-12-31 | -95.20% |
